Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 11/20 | 0.53 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3657158 | 0.99 | CSF1R (0.52) | CSF1RKITFLT3TBK1KDM5B | |
| Sulfuric Acid SCHEMBL18297749 | 0.93 | CSF1R (0.53) | CSF1RKITFLT3TBK1KDM5B | |
| SCHEMBL31263320 | 0.93 | CSF1R (0.48) | CSF1RKITFLT3TBK1KDM5B | |
| SCHEMBL3659610 | 0.92 | CSF1R (0.54) | CSF1RKITFLT3TBK1 | |
| SCHEMBL31262973 | 0.90 | CSF1R (0.49) | CSF1RKITFLT3 | |
| SCHEMBL31263337 | 0.89 | CSF1R (0.44) | CSF1RKITFLT3TBK1KDM5B | |
| SCHEMBL16101143 | 0.88 | CSF1R (0.61) | CSF1RKITFLT3TBK1 | |
| SCHEMBL19808383 | 0.88 | CSF1R (0.53) | CSF1RKITFLT3KDM5B | |
| SCHEMBL3702958 | 0.86 | CSF1R (0.51) | CSF1RKITFLT3KDM5B | |
| SCHEMBL19264300 | 0.85 | CSF1R (0.41) | CSF1RKITFLT3TBK1KDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3208269-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-15 | — | — | EP | claimed |
| US-11214566-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-04 | — | — | US | disclosed |
| EP-3208269-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-15 | — | — | EP | disclosed |
| EP-3208269-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-15 | — | — | EP | disclosed |
| US-20200399254-A1 | Substituted Pyridine Derivatives Useful As C-FMS Kinase Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-24 | — | — | US | disclosed |
| US-10800764-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-13 | — | — | US | disclosed |
| US-20180346454-A1 | Substituted Pyridine Derivatives Useful As C-FMS Kinase Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-06 | — | — | US | disclosed |
| US-10071991-B2 | Substituted pyridine derivatives useful as c-fms kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-11 | — | — | US | disclosed |
| EP-3284742-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS | Janssen Pharmaceutica NV (BE) | 2018-02-21 | — | — | EP | disclosed |
| EP-2970232-B1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-14 | — | — | EP | disclosed |
| US-20140045789-A1 | PROCESS FOR THE PREPARATION OF C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-13 | — | — | US | disclosed |
| US-8497376-B2 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-30 | — | — | US | disclosed |
| US-8497376-B2 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-30 | — | — | US | disclosed |
| US-8497376-B2 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-30 | — | — | US | disclosed |
| EP-2215079-A1 | INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica N.V. (BE) | 2010-08-11 | — | — | EP | disclosed |
| US-20090105296-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105296-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105296-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
| WO-2009052237-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052237-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10071991-B2 | Substituted pyridine derivatives useful as c-fms kinase inhibitors | FLT3, ABL1, FES | CSF1R 99/4885KIT 12/4885FLT3 1/4885 |
| US-20180346454-A1 | Substituted Pyridine Derivatives Useful As C-FMS Kinase Inhibitors | FLT3, ABL1, FES | CSF1R 99/4885KIT 12/4885FLT3 1/4885 |
| US-20200399254-A1 | Substituted Pyridine Derivatives Useful As C-FMS Kinase Inhibitors | FLT3, ABL1, FES | CSF1R 99/4885KIT 12/4885FLT3 1/4885 |
| US-10800764-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | FLT3, ABL1, FES | CSF1R 99/4885KIT 12/4885FLT3 1/4885 |
| US-20090105296-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | CSF1R 59/4885KIT 108/4885FLT3 9/4885 |
| US-11214566-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | FLT3, ABL1, FES | CSF1R 99/4885KIT 12/4885FLT3 1/4885 |
| US-20140045789-A1 | PROCESS FOR THE PREPARATION OF C-FMS KINASE INHIBITORS | FLT3, FES, FER | CSF1R 76/4885KIT 24/4885FLT3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.